Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
NCT ID: NCT04381819
Last Updated: 2020-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-03-02
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Corona Study of Middle Norway
NCT05638178
Mechanisms for Covid-19 Disease Complications
NCT04314232
Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital
NCT04345536
The Corona and COVID-19 Study in Telemark and Agder
NCT04514003
Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection
NCT04728919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At Oslo University Hospital, an observational study on the newly discovered emerging SARS- CoV-2, the coronavirus that causes COVID-19 infection has started. The study has been approved by the Regional Ethics Committee, so that inclusion of confirmed COVID-19 cases admitted at the hospital can start immediately including the first patients needing hospitalisation. The plan is to include more hospitals in other parts of Norway, starting with inclusion of Akershus University Hospital, Vestre Viken Drammen Hospital and Østfold Hospital. The study is anticipated to provide much needed data on the course of the COVID-19 infection, as well as generating knowledge about the virus and its transmission.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS-CoV-2 PCR
SARS-CoV-2 E gene
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Akershus
OTHER
Vestre Viken Hospital Trust
OTHER
Ostfold Hospital Trust
OTHER
Haukeland University Hospital
OTHER
University Hospital of North Norway
OTHER
St. Olavs Hospital
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan Cato Holter
Project leader, medical doctor, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fredrik G Müller, Professor
Role: STUDY_DIRECTOR
University of Oslo
Susanne G Dudman, Professor
Role: STUDY_CHAIR
University of Oslo
Jan C Holter, PhD
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vestre Viken Drammen Hospital
Drammen, Akershus, Norway
Haukeland University Hospital
Bergen, , Norway
Østfold Hospital Trust
Fredrikstad, , Norway
Akershus University Hospital
Lørenskog, , Norway
Oslo University Hospital
Oslo, , Norway
University Hospital North Norway
Tromsø, , Norway
St Olavs Hospital
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lars Heggelund, PhD
Role: primary
Role: backup
Bjørn Blomberg, PhD
Role: primary
Jonas Bergan, phd
Role: primary
Christian Prebensen, PhD
Role: primary
Anders B Kildal, PhD
Role: primary
Erik Solligård, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Troseid M, Holter JC, Holm K, Vestad B, Sazonova T, Granerud BK, Dyrhol-Riise AM, Holten AR, Tonby K, Kildal AB, Heggelund L, Tveita A, Boe S, Muller KE, Jenum S, Hov JR, Ueland T; Norwegian SARS-CoV-2 study group. Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19. Crit Care. 2023 Feb 23;27(1):69. doi: 10.1186/s13054-023-04356-2.
Tveita A, Murphy SL, Holter JC, Kildal AB, Michelsen AE, Lerum TV, Kaarbo M, Heggelund L, Holten AR, Finbraten AK, Muller KE, Mathiessen A, Boe S, Fevang B, Granerud BK, Tonby K, Lind A, Dudman SG, Henriksen KN, Muller F, Skjonsberg OH, Troseid M, Barratt-Due A, Dyrhol-Riise AM, Aukrust P, Halvorsen B, Dahl TB, Ueland T; NOR-SOLIDARITY Consortium and the Norwegian SARS-CoV-2 Study Group Investigators. High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19. J Infect Dis. 2022 Dec 13;226(12):2150-2160. doi: 10.1093/infdis/jiac313.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-04072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.